Parion Sciences Announces Presentation of Clinical Data With Novel Pulmonary Delivery Device
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, recently announced that an abstract from its pulmonary research and development efforts was presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, FL, October 27 through 29, 2016.
The accepted abstract is titled Pulomnary Aerosol Deposition in Children With Cystic Fibrosis Following Transnasal Delivery of Hypertonic Saline and is poster No. 459. The poster included deposition, safety, and tolerability data from the trial of a novel transnasal delivery device to deliver hypertonic saline to the lungs of children with Cystic Fibrosis. The transnasal delivery device used in the study was developed and tested with the support of the Cystic Fibrosis Foundation.
Parion Sciences is a development-stage biopharmaceutical company dedicated to research, development, and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging its scientific expertise in epithelial biology to expand its platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, visit www.Parion.com.
Total Page Views: 880
